Assessment of Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest CT and Pulmonary Function Tests

COVID-19 Pneumonia Clinical Trial

Official title:

A Multicentric Prospective Study: Assessment of Pulmonary Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest Computed Tomography and Pulmonary Function Tests

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05835128
• Other study ID #: UAIF 96/2020
• Status: Active, not recruiting
• Start date: March 1, 2020
• Est. completion date: December 31, 2024

Study information

• Verified date: September 2023
• Source: Centro Hospitalar Universitario do Algarve
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this prospective multicentric study is to evaluate the presence of long-term pulmonary sequelae in patients who had required hospitalization for treating COVID-19 pneumonia, trough chest CT and pulmonary function tests (PFT). Secondly we would like to evaluate the possible correlation between the chest CT findings and pulmonary function tests pre-existing co-morbidities and type of therapy used during hospitalization.

Description:

The investigators will invite to participate in this study patients who had been hospitalized with positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , namely with positive reverse transcription polymerase chain reaction or positive rapid antigen test, and with respiratory insufficiency (at admission or developed during hospital stay), or with viral pneumonia documented with thorax x-ray or Chest CT, during the period between march 2020 and march 2022. Patients who agree to participate and sign the informed consent will be enrolled in the study. Participants will be evaluate in two different periods: approximately 4 to 6 months after hospital discharge and approximately 12 to 14 months after hospital discharge. The first evaluation includes a physical examination at medical post-COVID-19 consultation, pulmonary function tests and reduced dose chest CT. The second evaluation includes a physical examination at medical post-COVID-19 consultation, and will include reduced dose chest CT and pulmonary function tests only if there were significative findings on those exams on the first evaluation, or if there are any clinical significative findings at the present moment. All the evaluations must respect the following time intervals: the pulmonary function tests and the chest CT will be done within a 6 week maximum interval of each other, and both of these examinations will be done within a 8 week maximum interval regarding the clinical evaluation. Demographic and clinical data will be collected by qualified clinical study staff (i.e., by physicians who conduct the post-COVID-19 medical consultation) and the patient will given the EuroQol 5 Dimension 5 Level questionnaire (EQ-5D-3L) to assess the health status. The reduced dose Chest CT will be obtained with the patient in a supine position and with breath-holding following inspiration, in a spiral acquisition mode with a 1 ,5 mm slice thickness and the images will be reviewed by four senior radiologist blinded to clinical and respiratory functional tests results. The pulmonary function tests will be interpreted according to the American Thoracic Society and European Respiratory Society guidelines 2022. The parameters measured included the forced expiratory flow between 25% and 75% of forced vital capacity (FVC), forced expiratory volume (FEV1), FVC/FEV1, vital capacity, total lung capacity, residual volume and the diffusing capacity of lung for carbone monoxide (DLCO), DLCO/Alveolar Volume (AV).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 250
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• at least 18 years old of age;
• positive SARS-CoV-2 reverse transcription-polymerase chain reaction on a nasopharyngeal and/or oropharyngeal swab or positive SARS-CoV-2 rapid antigen test
• hospitalization in one of two hospitals of our institution (university center) in consequence of SARS-CoV-2 related disease between march of 2020 and march of 2022 and

having :

• respiratory insufficiency when admitted or developing after admission or image documented viral pneumonia ;
• at least one thorax x-ray or lung CT acquired during the hospitalization period

Exclusion Criteria:

• previous lung cancer
• previous intersticial lung disease

Related Conditions & MeSH terms

• Communicable Diseases
• Coronavirus Infections
• COVID-19
• COVID-19 Pneumonia
• Infections
• Pneumonia
• Respiratory Function Impaired
• Respiratory Insufficiency
• SARS-CoV 2 Pneumonia
• Sequelae of; Infection

Locations

Country	Name	City	State
Portugal	Hospital de Faro (CHUA)	Faro
Portugal	Hospital de Portimâo (CHUA)	Portimão

Sponsors (2)

Lead Sponsor	Collaborator
Centro Hospitalar Universitario do Algarve	Universidade do Algarve

Country where clinical trial is conducted

Portugal, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of structural lung sequelae after COVID-19 pneumonia	evaluate the presence of lung structural sequelae with chest CT	12 -14 months
Primary	Prevalence of functional lung impairment after COVID-19 pneumonia	evaluate the presence of impaired PFT after COVID-19 pneumonia	12 -14 months
Primary	Association between chest CT findings and PFT impairment after COVID-19 pneumonia	evaluate the possible correlation between the presence of pulmonary structural alterations on chest CT and the presence of impaired PFT	12-14 months
Secondary	Prevalence of structural lung sequelae after COVID-19 pneumonia	evaluate the presence of lung structural sequelae with chest CT	4-6 months
Secondary	Prevalence of functional lung impairment after COVID-19 pneumonia	evaluate the presence of impaired PFT after COVID-19 pneumonia	4-6 months
Secondary	Association between chest CT findings and PFT impairment after COVID-19 pneumonia	evaluate the possible correlation between the presence of pulmonary structural alterations on chest CT and the presence of impaired PFT	4-6 months
Secondary	Association between chest CT findings after COVID-19 pneumonia and therapy used during hospitalization	to evaluate if there is any association between the presence of lung structural sequelae on chest CT and the different treatments used during hospitalization (corticotherapy, oxygen therapy, mechanical ventilation)	4-6 months
Secondary	Association between chest CT findings after COVID-19 pneumonia and therapy used during hospitalization	to evaluate if there is any association between the presence of lung structural sequelae on chest CT and the different treatments used during hospitalization (corticotherapy, oxygen therapy, mechanical ventilation)	12-14 months
Secondary	Association between chest CT findings after COVID-19 pneumonia and pre-existing co-morbidities	to evaluate if there is any association between the presence of lung structural sequelae on chest CT and pre-existing co-morbidities (diabetes, asthma, hypertension, dyslipidaemia, obesity, chronic obstructive pulmonary disease, cigarette smoking, heart disease and kidney disease)	4-6 months
Secondary	Association between chest CT findings after COVID-19 pneumonia and pre-existing co-morbidities	to evaluate if there is any association between the presence of lung structural sequelae on chest CT and pre-existing co-morbidities (diabetes, asthma, hypertension, dyslipidaemia, obesity,, chronic obstructive pulmonary disease, cigarette smoking, heart disease and kidney disease)	12 -14 months